PDS Biotech (PDSB) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti

PDS Biotech (PDSB) korporativ emblemasi va logotipi

PDS Biotechnology (PDSB) saraton vaksinalarini sinov bosqichida qolganligi sababli narxlarni belgilash imkoniyatiga ega emas, biznesning baholanishi esa -3.30 ko'rsatkichi bilan tasdiqlanganidek, FDA qarorlariga bog'liqdir. NCI va global texnologik gigantlar bilan hamkorlik viruslar va o'smalarga qarshi davolash vositalarini ishga tushirishni tezlashtirmoqda. Jori aksiya narxining ushbu grafigi Versamune tizimi va qat'iy sinov protokollari orqali T-hujayra javobi ekotizimini yaratayotgan kompaniyaning dinamikasini aks ettiradi.

PDSB pdsbiotech.com: Narx-foyda koeffitsiyenti 04.07.2022 - 10.11.2026 oraligʻida

PDS Biotechnology kompaniyasining tahliliy kesimlari

- bozor narxi va tahlilchilarning maqsadli narxlari:
Kompaniyaning har tomonlama tahlili:PDSB pdsbiotech.com
PDS Biotechnology ishlab chiqargan mahsulot

P/E koeffitsiyenti bozor kapitalizatsiyasining sof foydaga nisbatini ko'rsatish orqali investitsiyalarning qoplanish muddatini aks ettiradi va aktiv uchun to'langan premiumni aniqlash imkonini beradi. PDS Biotechnology (PDSB) kompaniyasining choraklik P/E koeffitsiyentini tahlil qilish juda muhimdir, chunki maxsus immunoterapiya platformalari va klinik sinovlar bosqichi daromadning yuqori tebranishlarini keltirib chiqaradi, bu esa ushbu grafikni mahalliy cho'qqilarda sotib olishdan qochish vositasiga aylantiradi.

Raqobatdosh kompaniyalar

Kapitalizatsiyaning foydaga nisbati immunitybio.com IBRX|P/E multiplikatori IMCR|Janux Therapeutics Inc (JANX) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Arcus Bio - Narx-foyda koeffitsiyenti|Zymeworks Biopharmaceuticals (ZYME) - Kapitalizatsiyaning foydaga nisbati|TNGX: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati IOVA (iovance.com)|IMTX: P/E multiplikatori|XNCR - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Compass Bio|Narx-foyda koeffitsiyenti Replimune Inc. (REPL)|Narxning foydaga nisbati Lyell Immunopharma (LYEL)|Narx-foyda koeffitsiyenti innate-pharma.com IPHA|Pyxis Oncology - Narx-foyda koeffitsiyenti|P/E multiplikatori Compugen Ltd CGEN|IOBT - Narxning foydaga nisbati|STRO (Sutro Biopharma, Inc) - Narx-foyda multiplikatori|MiNK Therapeutics, Inc. (INKT) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Werewolf Therapeutics, Inc. (HOWL)|Narx-foyda koeffitsiyenti IMMX|ALXO - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Narx-foyda koeffitsiyenti CUE (Cue Biopharma, Inc.)|Bozor narxining sof foydaga nisbati SONN|P/E multiplikatori MAIA (MAIA Biotechnology)|Kompaniya qiymatining sof foydaga nisbati LIMN|Lava Tx - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati NextCure Inc|leaptx.com (LPTX) - Narxning foydaga nisbati|Intensity Therapeutics, Inc. - Kompaniya qiymatining sof foydaga nisbati|SNSE (Sensei Biotherapeutics Inc) - P/E multiplikatori|P/E multiplikatori therivabio.com|Narxning foydaga nisbati Gritstone bio, Inc. (GRTS)|KA: Kapitalizatsiyaning sof foydaga nisbati|NexImmune Corp - Narx-foyda koeffitsiyenti|Turnstone Biologics Corp (TSBX) - Kapitalizatsiyaning foydaga nisbati|VCNX - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati HARP